Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
NCT03890289 · Fondazione Italiana Linfomi - ETS · PHASE2 · terminated · last registry update 2024-11-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was halted prematurely due to safety, since tocity stopping rules have been met” | – | Registry record, Fondazione Italiana Linfomi - ETS |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CD within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-03Also stopped (terminated): Incyte Corporation, parsaclisinib + placebo (NCT05073458)
- 2025-10-21Also stopped (terminated): Incyte Corporation, parsaclisib + ruxolitinib (NCT04551066)
- 2025-10-02Also stopped (terminated): Incyte Corporation, parsaclisib + ruxolitinib (NCT04551053)
- 2025-10-01Also stopped (terminated): National Cancer Institute (NCI), Copanlisib + Pertuzumab (NCT04108858)
- 2025-09-08Also stopped (terminated): Institut Curie, PF-05212384 (NCT02438761)
- 2025-08-24Phase 3 first posted: Dizal Pharmaceuticals, DZD8586 + Bendamustine (NCT07139873)
- 2025-08-08Also stopped (terminated): Fondazione Italiana Linfomi - ETS, Copanlisib (NCT04433182)
- 2025-08-03Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Durvalumab (NCT03842228)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-22Also stopped (terminated): Cancer Trials Ireland, Copanlisib + Trastuzumab emtansine (NCT04042051)
- 2025-07-11Results posted on the registry: M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2025-06-17Results posted on the registry: Gilead Sciences, Tirabrutinib + Idelalisib (NCT02457598)
- 2025-06-17Also stopped (terminated): Gilead Sciences, Tirabrutinib + Idelalisib (NCT02457598)
- 2025-06-15Also stopped (withdrawn): VA Office of Research and Development, copanlisib + Avelumab (NCT05687721)
- 2025-05-26Also stopped (terminated): Mayo Clinic, Belinostat + Carfilzomib (NCT03432741)
- 2025-05-22Also stopped (withdrawn): Inhye Ahn, Ibrutinib + Copanlisib (NCT04685915)
- 2025-04-16Results posted on the registry: National Cancer Institute (NCI), Copanlisib (NCT06400238)
- 2025-04-16Results posted on the registry: National Cancer Institute (NCI), Copanlisib (NCT06360588)
- 2025-03-24Results posted on the registry: Kazia Therapeutics Limited, Paxalisib (GDC-0084) (NCT03522298)
- 2025-03-07Results posted on the registry: Loxo Oncology, Inc., Pirtobrutinib + Idelalisib (NCT04666038)
- 2025-03-04Results posted on the registry: Columbia University, Copanlisib (NCT04750941)
- 2025-03-04Also stopped (terminated): Columbia University, Copanlisib (NCT04750941)
- 2025-02-28Results posted on the registry: Memorial Sloan Kettering Cancer Center, Vemurafenib + Copanlisib (NCT04462471)
- 2025-02-27Results posted on the registry: Jennifer R. Brown, MD, PhD, Acalabrutinib + Umbralisib (NCT04624633)
- 2025-02-26Phase 3 first posted: BeOne Medicines, Tacabrutideg + Bendamustine (NCT06846671)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision